1093.HK · HKG · Healthcare
CSPC Pharmaceutical Group Limited
Also onConsensus Drift
Implied value per share
HKD 5.20
Market price
HKD 8.93
Implied upside
-41.7%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · CNY model at 1.1708
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (CNY). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | CNY 24.5bn | CNY 23.2bn | CNY 21.9bn | CNY 20.6bn | CNY 19.5bn | -5.6% |
| EBIT | CNY 4.9bn | CNY 4.6bn | CNY 4.3bn | CNY 4.1bn | CNY 3.9bn | -5.6% |
| NOPAT | CNY 4.1bn | CNY 3.8bn | CNY 3.6bn | CNY 3.4bn | CNY 3.2bn | -5.6% |
| Add depreciation & amortisation | CNY 1.0bn | CNY 983.9m | CNY 928.6m | CNY 876.3m | CNY 827.1m | -5.6% |
| Less capital expenditure | CNY -2.0bn | CNY -1.9bn | CNY -1.8bn | CNY -1.7bn | CNY -1.6bn | -5.6% |
| Less increase in working capital | CNY 554.2m | CNY 523.0m | CNY 493.6m | CNY 465.8m | CNY 439.6m | +5.6% |
| Free cashflow to firm | CNY 3.6bn | CNY 3.4bn | CNY 3.2bn | CNY 3.1bn | CNY 2.9bn | -5.6% |
| Discount factor | 0.9576 | 0.8781 | 0.8052 | 0.7384 | 0.6771 | - |
| Present value | CNY 3.5bn | CNY 3.0bn | CNY 2.6bn | CNY 2.3bn | CNY 2.0bn | -13.5% |
| Present Value Of The Forecast | CNY 13.3bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 3.20% | HKD assumption - no free live source available for this market (assumption) |
| Equity risk premium | 7.00% | Market assumption |
| Beta | 0.839 | Reported 0.760, pulled toward 1.0 (Blume) |
| Cost of equity | 9.07% | Risk-free + beta x equity risk premium |
| Cost of debt | 6.72% | Interest expense / average total debt |
| Market capitalisation | CNY 101.9bn | 99.4% of capital |
| Total debt | CNY 641.1m | 0.6% of capital, book value as a proxy |
| Tax rate | 16.5% | Effective, capped at statutory |
| WACC | 9.05% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
69% of EV
- Forecast FCFF, final year
- CNY 2.9bn
- Capex at depreciation, working capital in reinvestment
- CNY 3.3bn
- Less reinvestment at g/ROIC (15.9% of NOPAT)
- CNY -522.6m
- Capitalised
- CNY 2.8bn
- ROIC (reported)
- 15.7%
- Terminal value, undiscounted
- CNY 43.2bn
- Terminal value, discounted
- CNY 29.2bn
- Enterprise value
- CNY 42.6bn
- Less net debt
- CNY -8.2bn
- Equity value
- CNY 50.8bn
Exit at 16.7x EBITDA
80% of EV
- Terminal value, undiscounted
- CNY 78.3bn
- Terminal value, discounted
- CNY 53.0bn
- Enterprise value
- CNY 66.3bn
- Less net debt
- CNY -8.2bn
- Equity value
- CNY 74.6bn
Spread between methods: 38%.
Sensitivity
Value per share (CNY) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 7.05% | 5.43 | 5.66 | 5.94 | 6.28 | 6.72 |
| 8.05% | 4.75 | 4.89 | 5.06 | 5.26 | 5.49 |
| 9.05% | 4.25 | 4.34 | 4.45 | 4.56 | 4.70 |
| 10.05% | 3.87 | 3.93 | 3.99 | 4.07 | 4.16 |
| 11.05% | 3.56 | 3.60 | 3.65 | 3.70 | 3.75 |
Outlined: this model. Green text: above today's price of 7.63. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | -5.6% | 11.2% | +16.8pp |
| EBIT margin | 19.8% | 36.3% | +16.5pp |
| Discount rate | 9.1% | 5.9% | -3.2pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.